MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- DISHMAN PHARMA - TORRENT PHARMA
DISHMAN PHARMA vs TORRENT PHARMA - Comparison Results
DISHMAN PHARMA Change
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
TORRENT PHARMA 
Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More
Current Valuations
| DISHMAN PHARMA | TORRENT PHARMA | DISHMAN PHARMA/ TORRENT PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 25.1 | 38.9 | 64.6% | View Chart |
| P/BV | x | 3.3 | 8.4 | 39.7% | View Chart |
| Dividend Yield | % | 0.7 | 0.7 | 91.9% |
Financials
 DISHMAN PHARMA  TORRENT PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DISHMAN PHARMA Mar-16 |
TORRENT PHARMA Mar-19 |
DISHMAN PHARMA/ TORRENT PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 374 | 1,964 | 19.1% | |
| Low | Rs | 129 | 1,245 | 10.4% | |
| Sales per share (Unadj.) | Rs | 197.8 | 453.4 | 43.6% | |
| Earnings per share (Unadj.) | Rs | 21.2 | 25.8 | 82.2% | |
| Cash flow per share (Unadj.) | Rs | 34.7 | 62.3 | 55.7% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 17.00 | 11.8% | |
| Dividend yield (eoy) | % | 0.8 | 1.1 | 75.0% | |
| Book value per share (Unadj.) | Rs | 179.9 | 279.2 | 64.4% | |
| Shares outstanding (eoy) | m | 80.69 | 169.22 | 47.7% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 1.3 | 3.5 | 36.0% | |
| Avg P/E ratio | x | 11.9 | 62.2 | 19.1% | |
| P/CF ratio (eoy) | x | 7.2 | 25.8 | 28.1% | |
| Price / Book Value ratio | x | 1.4 | 5.7 | 24.3% | |
| Dividend payout | % | 9.4 | 65.9 | 14.3% | |
| Avg Mkt Cap | Rs m | 20,306 | 271,513 | 7.5% | |
| No. of employees | `000 | 0.8 | 13.6 | 6.1% | |
| Total wages/salary | Rs m | 5,355 | 14,038 | 38.1% | |
| Avg. sales/employee | Rs Th | 19,252.7 | 5,642.6 | 341.2% | |
| Avg. wages/employee | Rs Th | 6,459.5 | 1,032.4 | 625.7% | |
| Avg. net profit/employee | Rs Th | 2,064.1 | 320.9 | 643.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 15,961 | 76,728 | 20.8% | |
| Other income | Rs m | 265 | 571 | 46.5% | |
| Total revenues | Rs m | 16,226 | 77,299 | 21.0% | |
| Gross profit | Rs m | 4,103 | 19,831 | 20.7% | |
| Depreciation | Rs m | 1,091 | 6,177 | 17.7% | |
| Interest | Rs m | 944 | 5,038 | 18.7% | |
| Profit before tax | Rs m | 2,334 | 9,187 | 25.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 1 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -3,570 | 0.0% | |
| Tax | Rs m | 624 | 1,254 | 49.7% | |
| Profit after tax | Rs m | 1,711 | 4,363 | 39.2% | |
| Gross profit margin | % | 25.7 | 25.8 | 99.5% | |
| Effective tax rate | % | 26.7 | 13.6 | 195.8% | |
| Net profit margin | % | 10.7 | 5.7 | 188.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,018 | 50,375 | 21.9% | |
| Current liabilities | Rs m | 9,517 | 51,653 | 18.4% | |
| Net working cap to sales | % | 9.4 | -1.7 | -564.7% | |
| Current ratio | x | 1.2 | 1.0 | 118.7% | |
| Inventory Days | Days | 110 | 92 | 120.0% | |
| Debtors Days | Days | 35 | 68 | 51.0% | |
| Net fixed assets | Rs m | 16,304 | 83,648 | 19.5% | |
| Share capital | Rs m | 161 | 846 | 19.1% | |
| "Free" reserves | Rs m | 12,907 | 46,397 | 27.8% | |
| Net worth | Rs m | 14,516 | 47,244 | 30.7% | |
| Long term debt | Rs m | 4,189 | 39,129 | 10.7% | |
| Total assets | Rs m | 29,805 | 141,209 | 21.1% | |
| Interest coverage | x | 3.5 | 2.8 | 122.9% | |
| Debt to equity ratio | x | 0.3 | 0.8 | 34.8% | |
| Sales to assets ratio | x | 0.5 | 0.5 | 98.6% | |
| Return on assets | % | 8.9 | 6.7 | 133.8% | |
| Return on equity | % | 11.8 | 9.2 | 127.6% | |
| Return on capital | % | 17.5 | 12.3 | 142.1% | |
| Exports to sales | % | 24.8 | 0 | - | |
| Imports to sales | % | 3.7 | 0 | - | |
| Exports (fob) | Rs m | 3,956 | NA | - | |
| Imports (cif) | Rs m | 596 | NA | - | |
| Fx inflow | Rs m | 4,952 | 22,103 | 22.4% | |
| Fx outflow | Rs m | 697 | 5,522 | 12.6% | |
| Net fx | Rs m | 4,255 | 16,581 | 25.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,786 | 17,981 | 15.5% | |
| From Investments | Rs m | -1,529 | -2,413 | 63.4% | |
| From Financial Activity | Rs m | -941 | -13,145 | 7.2% | |
| Net Cashflow | Rs m | 316 | 2,380 | 13.3% | |
Share Holding
| Indian Promoters | % | 61.4 | 71.5 | 85.9% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 3.7 | 7.0 | 52.7% | |
| FIIs | % | 12.7 | 12.6 | 100.8% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 22.1 | 8.8 | 251.1% | |
| Shareholders | 46,261 | 26,511 | 174.5% | ||
| Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: ORCHID PHARMA LTD CIPLA ASTRAZENECA PHARMA VENUS REMEDIES STERLING BIOTECH
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Ends 143 Points Lower; Banking and Finance Stocks Witness Selling(Closing)
Indian share markets witnessed selling pressure throughout the day today, tracking weak global cues as coronavirus cases continue to surge across the world.
Related Views on News
TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)
Jan 28, 2020 | Updated on Jan 28, 2020For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)
Nov 1, 2019 | Updated on Nov 1, 2019For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)
Jul 25, 2019 | Updated on Jul 25, 2019For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)
May 22, 2019 | Updated on May 22, 2019For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)
Jan 31, 2019 | Updated on Jan 31, 2019For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
More Views on NewsMost Popular
How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)
Jul 2, 2020In the first of two videos, I'll show you how to identify the best stocks for intraday trading.
Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)
Jul 2, 2020Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...
A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)
Jun 30, 2020If you are a trader, you must watch out for this dangerous addiction.
Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)
Jul 3, 2020This is why I believe smallcaps are the place to be in the near future.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2020
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
DISHMAN PHARMA SHARE PRICE
May 29, 2017 (Close)
TRACK DISHMAN PHARMA
- Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DISHMAN PHARMA
DISHMAN PHARMA 8-QTR ANALYSIS
COMPARE DISHMAN PHARMA WITH
FEATURED VIDEOS
![]( "What No One Told You About Finding the Best Penny Stocks")
What No One Told You About Finding the Best Penny Stocks![]( "Using Price Action to Identify Trading Opportunity in Defense Stocks")
Using Price Action to Identify Trading Opportunity in Defense Stocks![]( "Three Charts on One of the Quickest Bull Markets in History")
Three Charts on One of the Quickest Bull Markets in History![]( "This is Where You Will Find the Most Promising Bets for Post Covid Rebound")
This is Where You Will Find the Most Promising Bets for Post Covid Rebound![]( "Here")
Here's How You Can Make Big Money from Penny Stocks
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.